乳腺癌组织中miR-375 SLC7A11表达与病理分型及预后的关系

doi:10.3969/j.issn.1006-6233.2025.12.017

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1351 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 探讨乳腺癌组织中微小核糖核酸-375(miR-375)、溶质载体家族7成员11(SLC7A11)表达与病理分型及预后的关系。方法: 选取2017年1月至2021年3月在辽宁省健康产业集团阜新矿总医院行乳腺癌根治术的乳腺癌患者150例,采用实时荧光定量聚合酶链式反应检测乳腺癌组织及对应癌旁组织miR-375、SLC7A11的mRNA表达。通过Pearson相关系数分析miR-375与SLC7A11 mRNA在乳腺癌组织表达的相关性;根据乳腺癌组织miR-375、SLC7A11 mRNA表达的中位数分为高/低表达组,Kaplan-Meier法绘制各组患者无进展生存曲线;以乳腺癌患者预后为因变量,多因素Cox回归分析影响乳腺癌患者预后的因素。结果: 与癌旁组织相比,乳腺癌组织miR-375表达降低,SLC7A11 mRNA表达升高(P<0.05)。miR-375与SLC7A11 mRNA在乳腺癌组织表达呈负相关(r=-0.757,P<0.05)。与中高分化、TNM分期Ⅰ~Ⅱ期、无淋巴结转移乳腺癌组织比较,低分化、TNM分期Ⅲ期、淋巴结转移乳腺癌组织中miR-375表达降低,SLC7A11 mRNA表达升高(P<0.05)。150例乳腺癌患者3年无进展生存率为75.33%(113/150)。miR-375高表达患者3年无进展生存率90.79%,明显高于miR-375低表达患者的59.46%;SLC7A11 mRNA高表达患者3年无进展生存率60.98%。明显低于SLC7A11 mRNA低表达患者的92.65%(P<0.05)。多因素Cox回归显示,miR-375≥1.10与SLC7A11 mRNA≥1.05分别为乳腺癌患者不良预后的独立保护因素与危险因素(P<0.05)。结论: 乳腺癌组织中miR-375低表达和SLC7A11 mRNA高表达,与病理分型和预后不良有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郭东旭
	尚悦
	齐中华

关键词 ：乳腺癌, 微小核糖核酸-375, 溶质载体家族7成员11

Abstract：Objective: To investigate the relationship between the expression of miR-375 and solute carrier family 7 member 11 (SLC7A11) in breast cancer tissues with pathological subtypes and prognosis. Methods: A total of 150 breast cancer patients who underwent radical mastectomy in Fuxin Mining General Hospital of Liaoning Health Industry Group from January 2017 to March 2021 were selected. Real-time quantitative polymerase chain reaction was used to detect the expression of miR-375 and SLC7A11 messenger RNA (mRNA) in breast cancer tissue and corresponding adjacent normal tissues. Pearson correlation analysis was performed to evaluate the correlation between miR-375 and SLC7A11 mRNA expression in breast cancer tissue. Patients were divided into high- and low-expression groups based on the median expression levels of miR-375 and SLC7A11 mRNA. Kaplan-Meier curves were used to analyze progression-free survival (PFS) in different groups. Multivariate Cox regression analysis was conducted to identify prognostic factors for breast cancer patients. Results: Compared to adjacent normal tissues, miR-375 expression was significantly down-regulated, whereas SLC7A11 mRNA expression was significantly up-regulated in breast cancer tissue (P＜0.05). A negative correlation was observed between miR-375 and SLC7A11 mRNA expression in breast cancer tissue (r＝－0.757,P＜0.05). miR-375 expression was lower, and SLC7A11 mRNA expression was higher in poorly differentiated tumors, TNM stage III tumors, and tumors with lymph node metastasis compared to moderately-to-well differentiated tumors, TNM stage I–II tumors, and tumors without lymph node metastasis (P＜0.05). The 3-year PFS rate among the 150 breast cancer patients was 75.33% (113/150). Patients with high miR-375 expression had a significantly higher 3-year PFS rate (90.79%) compared to those with low miR-375 expression (59.46%), while patients with high SLC7A11 mRNA expression had a significantly lower 3-year PFS rate (60.98%) compared to those with low SLC7A11 mRNA expression (92.65%) (P＜0.05). Multivariate Cox regression analysis showed miR-375 ≥1.10 was identified as an independent protective factor, whereas SLC7A11 mRNA ≥1.05 was an independent risk factor for poor prognosis in breast cancer patients (P＜0.05). Conclusion: Low expression of miR-375 and high expression of SLC7A11 mRNA in breast cancer tissues are associated with unfavorable pathological subtypes and poor prognosis.

Key words： Breast cancer Micro ribonucleic acid-375 Solute carrier family 7 member 11

基金资助:辽宁省卫生健康委科研课题,(编号:202001077)

引用本文:

郭东旭, 尚悦, 齐中华. 乳腺癌组织中miR-375 SLC7A11表达与病理分型及预后的关系[J]. 河北医学, 2025, 31(12): 2043-2049.
GUO Dongxu, SHANG Yue, QI Zhonghua. Expression of miR-375 and SLC7A11 in Breast Cancer Tissue and Their Relationship with Pathological Subtypes and Prognosis. HeBei Med, 2025, 31(12): 2043-2049.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2025.12.017 或 http://www.hbyxzzs.cn/CN/Y2025/V31/I12/2043

[1] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
[2] Abolhasanzadeh N,Sarabandi S,Dehghan B,et al.Exploring the intricate relationship between miRNA dysregulation and breast cancer development:insights into the impact of environmental chemicals[J].Front Immunol,2024,5(15):1333563.
[3] 于昌盛,方芳,陈剑平,等.miR-375在乳腺癌增殖和临床预后相关性中的研究[J].皖南医学院学报,2022,41(5):432-435.
[4] 方宇辰,徐忆苏,许馨文,等.铁死亡调控机制治疗乳腺癌的研究进展[J].分子诊断与治疗杂志,2023,15(7):1279-1282.
[5] 刘晓轩,张驰,黄思琪,等.SLC7A11的调控机制及肿瘤治疗应用研究进展[J].中国肿瘤,2023,32(11):878-885.
[6] 李昕,栗东海,高小明,等.重楼皂苷通过p53/SLC7A11信号轴促进三阴性乳腺癌细胞铁死亡的机制研究[J].解放军医学杂志,2023,48(1):58-63.
[7] 赋能专科建设—共创健康中国多学科专家委员会,中国抗癌协会乳腺癌专业委员会,杨犇龙,等.乳腺癌多学科诊疗标准与规范(2023年版)[J].中国癌症杂志,2023,33(12):1188-1203.
[8] 卢金喜,余红梅,齐孝安,等.miR-375-3p过表达的甲状腺乳头状癌细胞增殖和侵袭能力变化[J].山东医药,2023,63(14):50-54.
[9] 叶星明,王淋,贾静,等.miR-375靶向YAP1调控上皮-间质转化参与乳腺癌细胞曲妥珠单抗的耐药[J].中国癌症杂志,2021,31(1):27-34.
[10] Chen H,Hou S,Zhang H,et al.MiR-375 impairs breast cancer cell stemness by targeting the KLF5/G6PD signaling axis[J].Environ Toxicol,2024,5(12):24204.
[11] Moorthy R K,Srinivasan C,Kannan M,et al.Deregulation of miR-375 inhibits HOXA5 and promotes migration,invasion,and cell proliferation in breast cancer[J].Appl Biochem Biotechnol,2023,195(7):4503-4523.
[12] 马国霞,王佳丽,闫宇,等.脂质代谢参与铁死亡机制及其在妇科恶性肿瘤治疗中的应用研究进展[J].山东医药,2024,64(8):99-102.
[13] Wang Z,Shen N,Wang Z,et al.TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11/xCT K11-linked ubiquitination and degradation[J].Cell Death Differ,2024,31(1):53-64.
[14] 李晓华,郭欣怡.Slc7a11通过E-cadherin/β-catenin信号通路诱导自噬促进乳腺癌细胞侵袭转移的作用机制研究[J].四川生理科学杂志,2023,45(1):1-4.
[15] Liu J,Yang H,Deng J,et al.CircRPPH1 promotes the stemness of gastric cancer cells by targeting miR-375/SLC7A11 axis[J].Environ Toxicol,2023,38(1):115-125.